Cell Therapeutics (CTIC) Il mio nome è Therapeutic! ...Cell therapeutic !.....2° atto (1 Viewer)

patt

Forumer storico
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Tuesday June 5, 7:00 am ET

ASCO publication highlights health care cost benefit of bioengineering paclitaxel


CHICAGO, June 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that data published in the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) abstracts showed reduced medical resource utilization (MRU) and associated costs with XYOTAX (paclitaxel polyglumex) treatment compared to gemcitabine or vinorelbine in treating patients with non-small cell lung cancer (NSCLC). The total average treatment cost, excluding drug costs, for XYOTAX patients was nearly half the cost of treatment for patients on standard chemotherapy ($2,518 vs. $4,834 per patient) and was associated with a significant reduction in many of the toxic side effects.
 

felixeco

Forumer storico
nn avevo + postato di qua

perchè ormai c'era+ poco da dire e pensavo fosse un forum morto
Dopo che l' 1 x 4 nn ha portato a niente, come detto nello Stock picking..........
ho mollato anche l'ultimo cip.Attendere che decuplichi se azzeccano il farmaco può avvenire tra 10 anni.Il rischio che vedo è che continui a scendere sino al prox auc :eek:
 
ENTRATO PRIMA DELLìAUMENTO DI CAPITALE ED USCITO CON OLTRE IL 50% DI PERDITA PER NON PERDERE TUTTO,MI HANNO DETTO CHE STA X FALLIRE,MEGLIO 2,20 CHE NIENTE.....MI SA CHE L'AUMENTO DI CAPITALE NON è STATO UGUALE PER TUTTI I POSSESSORI DEL TITOLO MA CHE QUALCUNO HA AVUTO DEI TITOLI NEL CONCAMBIO CHE POI HA SUBITO MESSO SUL MERCATO FACENDOLO CROLLARE.....UN BEL FALLIMENTO...PERFORTUNA POCA ROBA.
 

felixeco

Forumer storico
Re: cell

davidino79c ha scritto:
cell sta per fallire ma che dite? avete letto le notizie? 0ggi un bel + 17% domani ancora...

che dire ..auguri.
Ma visto cosa nn si sono inventati in questi anni...........e visto che ci sono altri titoli in borsa :eek:
 

patt

Forumer storico
Re: cell

felixeco ha scritto:
che dire ..auguri.
Ma visto cosa nn si sono inventati in questi anni...........e visto che ci sono altri titoli in borsa :eek:

..la cosa strana di questo rialzoè che ...a differenza di altri"strappi" si è verificato senza notizie di rilievo...e il titolo ha mantenuto vigore per piu' giorni.......si sta comportando in modo anomalo......di certo npn saranno state le parole di MR Bianco a dare il via agl'acquisti......forse qualcuno sa di piu' di quello che potremmo conoscere noi.....

mi sono perso questo rialzo e a l momento ne sto fuori...... :rolleyes:
 

patt

Forumer storico
supercell1 ha scritto:
Ciao a tutti, sono nuovo.
Vecchio di cell però (1 anno e mezzo circa..)

Dite che è iniziata l'inversione? Su questo forum dicono che a luglio usciranno i dati del pixantrone (www.meteofinanza.com) .. mi sembra strano..

ciao


non so se potremmo parlare di inversione...anche perche' troppe volte il titolo ha goduto di ottimi "rimbalzi" per poi metodicamente perdere il guadagnato e ritornare a scendere.....quanto posso pero' dirti che il rialzo in atto.....è nato senza notizie di rilievo e lo sta mantenendo per piu' giorni.....questa secondo me è la cosa inusuale..... :rolleyes:
 

patt

Forumer storico
Cell Therapeutics svela i conti




Cell Therapeutics (CTIC - notizie) (CTI (CTI.SN - notizie) ) ha comunicato i risultati finanziari del trimestre e del semestre chiusi il 30 giugno 2007. La perdita netta è stata pari a livello trimestrale a 27,9 milioni di dollari (0,65 dollari per azione) rispetto ai 20,5 milioni di dollari (0,78 dollari per azione) registrati nello stesso trimestre 2006. Mentre nel semestre la perdita è stata pari a 56,6 milioni di dollari (1,41 dollari per azione). Inoltre, la società biofarmaceutica ha chiuso il trimestre con 43,8 milioni di dollari in disponibilità liquide ed equivalenti a liquidità, titoli disponibili per la vendita e interessi da ricevere. “La recente acquisizione di Systems Meducine (SMi) è la prima di due operazioni volte al rafforzamento del nostro portafoglio prodotti ed al riposizionamento di CTI nel mercato oncologico” ha detto James A. Bianco, M.D., presidente e amministratore delegato di Cell Therapeutics. “Siamo in procinto di completare – ha aggiunto Bianco - la seconda operazione, acquisendo un prodotto già in commercializzazione per ripristinare la nostra presenza nel mercato Pubblicità


onco-ematologico”.
 

patt

Forumer storico
Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission



Significant Difference in Primary Endpoint Could be Acceptable With Fewer
Patients Than Originally Planned
SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) (MTAX: CTIC) announced today that following discussions with the U.S. Food and Drug Administration (FDA) regarding its EXTEND (PIX301) trial for patients with aggressive non-Hodgkin's lymphoma (NHL) the Company has decided to conduct a full analysis of the trial instead of an interim analysis as previously planned. The decision was based in part on the Agency's guidance that a primary endpoint analysis of less than the initially-projected 320 eligible patients could be acceptable for New Drug Application (NDA) submission if it is able to demonstrate a statistically significant (p<0>15 percent) was seen as well as clinically significant reductions in severe infections and febrile neutropenia.

The Data Safety Monitoring Committee, which met recently, recommended that the EXTEND study continue. The trial is expected to be completed by the end of 2007 with a full analysis during the first half of 2008. Since pixantrone has fast track status for relapsed, aggressive NHL, the drug could receive marketing approval in 2009.

About EXTEND (PIX301)

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who have received two or more prior therapies and who are sensitive to treatment with anthracyclines. The trial is being conducted at 130 sites in 17 countries. Patients are randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial is designed to examine the complete response (CR) or unconfirmed complete response (uCR) rate, time to tumor progression, and overall survival. The study was powered based on a CR rate assumption of less than 5 percent for the control arm and a 10 percent improvement in CR rate for the pixantrone arm. The study initially anticipated the requirement of 320 patients to meet the statistical assumptions of the trial. The study is being conducted under a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA) and pixantrone has received fast track designation for this indication.

About RAPID (PIX203)

The RAPID trial is a first-line randomized phase II study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone to part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate non-inferior complete response rates as the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com. This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, our ability and time needed to enroll, treat and evaluate eligible patients in our trials, the limitations inherent in having a smaller enrollment size, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise
 

Users who are viewing this thread

Alto